Destiny Pharma (DEST) is developing a pipeline of novel antimicrobials from its XF drug platform, to help combat highly prevalent and virulent bacteria. These include eight so far tested of those classed as urgent threats by the World Health Organisation and Centers for Disease Control (CDC), including MRSA (methicillin-resistant Staphylococcus aureus). The unique mechanism of DEST’s new class of drug candidates could also help to overcome Anti-Microbial Resistance (AMR) that is a major
13 Aug 2018
Clinical progress with XF drug platform
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clinical progress with XF drug platform
Destiny Pharma Plc (DEST:LON) | 21.5 -0.1 (-2.3%) | Mkt Cap: 20.5m
- Published:
13 Aug 2018 -
Author:
Emma Ulker -
Pages:
3
Destiny Pharma (DEST) is developing a pipeline of novel antimicrobials from its XF drug platform, to help combat highly prevalent and virulent bacteria. These include eight so far tested of those classed as urgent threats by the World Health Organisation and Centers for Disease Control (CDC), including MRSA (methicillin-resistant Staphylococcus aureus). The unique mechanism of DEST’s new class of drug candidates could also help to overcome Anti-Microbial Resistance (AMR) that is a major